chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Temp 100.7 F, chills, generalized body aches,  and excess fatigue.   Onset of symptoms occurred in the early morning hours the day after receiving the vaccine.  Symptoms completely resolved by the next morning.  Treatment was conservative with Tylenol, rest, and hydration.  I missed one day of work due to this brief episode.  I am a SARS COVID survivor who had a very severe / life threatening case of SARS COVID 19.    I was hospitalized and treated from March 28, 2020 to May 16, 2020.  Please feel free to contact me for any information that you may need.
Person was given 0.3cc dose of Janssen Booster dose instead of standard 0.5 cc. Health Department notified and Manufacturer (Janssen) notified and all persons reported to Janssen Manufacturer for their Pharmacy department, recommendations from the Manufacturer and with agreement from Health Department are to notify all of the recipients that received an incorrect dose and submit a VAERS report for each.
PATIENT RECEIVED VACCINE 9:58AM. AT TIME OF VACCINE INDICATED HE HAD NOT EATEN THAT MORNING, BUT THAT HE HAD NOT BEEN DIZZY FROM VACCINES IN THE PAST. WHILE SITTING IN POST-IMMUNIZATION AREA, PATIENT LOST PASSED OUT AND COLLAPSED FROM CHAIR TO FLOOR. REGAINED CONSCIOUSNESS SHORTLY THEREAFTER. BLOOD PRESSURE WAS TAKEN AND WAS 118/80 WITH PULSE OF 112. PARAMEDICS WERE CALLED AND UPON EXAMINATION, PATIENT'S BLOOD SUGAR WAS 62. PATIENT STABILIZED AND WAS ABLE TO LEAVE UNDER HIS OWN POWER. INDICATED THAT HIS NECK WAS A LITTLE BIT SORE
On the 5th days after the 2nd dose of Moderna Vaccine, I had skin rashes all over my body except face &  foot,   Next day, the rashes were little bit calm down, and 2 days later, all the rashes were gone.  During the rashes, no  other symptoms such as fever, tiredness etc.
A non-serious spontaneous report of wheezing has been received from a registered nurse concerning a 12-year-old female, subsequent to H1N1, Intranasal. The patient's medical history included asthma and seizure. No other concomitant medications have reported for this patient. On 10-Nov-2009, the patient received H1N1, Intranasal for an unknown indication. On 10-Nov-2009, after receiving the vaccine the patient experienced wheezing. The patient has been in contact with the pediatrician. The outcome of the event was unknown.
RespDepression, Syncope & DYSPNEA; SWELLING OF THROAT DIPHENHYDRAMINE 25 MG ONCE, METHYLPREDNISOLONE 125 MG ONCE, ALBUTEROL 1 neb by inhalation now
Swelling and redness at site that increased during the night. Fever of 99-100 degrees. Antibiotics ordered - INVANZ 1000mg IM x 2, AUGMENTIN 875mg 1 po BID x 7 days.
Measured a 101 Fever; Severely sore arm around injection site upon waking up; Chills; This is a spontaneous report from a contactable consumer (patient). This 31-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: ER8733) via unspecified route on left arm single dose for COVID-19 immunization on 19Apr2021 01:15 PM, at 31-year-old. Medical history included: Metabolic syndrome/Moderate obesity. Concomitant medication included: lovastatin from 09Apr2021. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number: ER8733) on right arm for COVID-19 immunization on 29Mar2021 12:30 PM, at 31-year-old. On 20Apr2021 04:30 AM, the patient had severely sore arm around injection site upon waking up, could not lift arm to put on jacket without significant pain, began taking ibuprofen (ADVIL). Chills set in during the day. Measured a 101 Fever with ibuprofen in system just after 5:00 PM. Outcome of the events was not resolved.  No follow-up attempts are needed. No further information is expected.
Fever, difficult to control x 1. Given Tylenol/Advil. Screaming x 3 hrs. Loose BM x 2. Temp 100.8. Coxsackievirus.
Fatigue and pain in the injection arm within a few hours of the vaccine. Extreme pain all over my body began around midnight the day after vaccination, and I could not sleep because of the pain. My entire body hurt, especially my back, hips, and the injection arm. I experienced chills and hot flashes on and off. I also experienced fatigue and weakness. These symptoms persisted throughout Friday (my vaccine was Thursday).  Ibuprofen helped ease the symptoms. I felt mostly normal on Saturday, with some lingering back pain and fatigue.
Felt sore at site in the morning; gradually got more body soreness; got a migraine headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 58-year-old female patient received BNT162b2 (BNT162B2), on 11Apr2022 at 18:00 as dose 4 (booster), single (Lot number: FK9894) at the age of 58 years intramuscular, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: BNT162b2 (dose number: 3, lot number: Ff2590, administrator route: Intramuscular, administration date: 08Oct2021, vaccine location: Left arm), administration date: 08Oct2021, when the patient was 58-year-old, for Covid-19 immunization; Covid-19 vaccine (Dose 2, Manufacturer Unknown), for Covid-19 immunization; Covid-19 vaccine (Dose 1, Manufacturer Unknown), for Covid-19 immunization.  The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 12Apr2022, outcome "recovering", described as "Felt sore at site in the morning"; MIGRAINE (non-serious) with onset 12Apr2022, outcome "recovered" (Apr2022), described as "got a migraine headache"; PAIN (non-serious) with onset 12Apr2022, outcome "recovered" (Apr2022), described as "gradually got more body soreness". Therapeutic measures were not taken as a result of vaccination site pain. Therapeutic measures were taken as a result of pain, migraine.  Additional information: If covid prior vaccination: No. If covid tested post vaccination: No. Got vaccine at 6PM on 11Apr2022. Felt sore at site in the morning of 12Apr2022, gradually got more body soreness and took Advil at 10AM with good results. At 5PM soreness gradually came back and got a migraine headache. Took Advil at 8PM and slept through the night. Only experiencing site soreness on morning of 13Apr2202 and went to work.   No follow-up attempts are possible. No further information is expected.
SICK; This spontaneous report received from a consumer concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested.  No concomitant medications were reported. On an unspecified date, the subject experienced sick. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of sick was not reported. This report was non-serious. This case is associated with PQC no. 90000176125. The suspected product quality complaint has been confirmed to be no PQC was identified within the complaint reported.  Complaint has been approved for void, based on the PQC evaluation/investigation performed.
received 1st dose 10/16/2021, 2nd not administered; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (The patient 1st dose of Shingrix on 16th October 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.    Additional Information: GSK Receipt Date: 24-OCT-2022 Reporter's Comment: The reporter stated that the patient never returned back over the weekend to get 2nd dose.  The reporter also stated that 2nd dose had not been administered at time of call. No additional data available. The reporter give consent to follow up. Additional Supportive Information: The patient had not received 2nd dose which led to incomplete course of vaccination. This case is linked with US2022153073, reported by the same reporter.; Sender's Comments:  US-GSK-US2022153073:Same reporter
4/9/2021   Patient was observed post Covid-19 immunization for 15 minutes .  During the observation period, she experienced an adverse reaction with the following symptoms:  dizziness.   Assessment : Time of assessment 0503pm. Alert and oriented.   Actions taken:  Vitals sign taken  VAERS form obtained and completed by RN. VS at 1703pm  BP- 105/53, P- 77, O2- 100%, water given, 1710pm- BP- 104/60, P- 79, O2- 100%, VS at 1718pm BP-108/66, P- 67, O2- 100%       Medications administered: No medication administered.   Disposition:The Patient was provided with Vaccine Information Sheet and instruction to access the V-Safe system.  Discharged with no further complaints.     Immunizations Administered    Name Date Dose VIS Date Route   Pfizer COVID-19 Vaccine 4/9/2021  4:43 PM 0.3 mL 12/11/2020 Intramuscular   Manufacturer: Pfizer, Inc
About an hour after administering MMR, she broke out in hives. Hydrocortisone cream, hydrocortisone by mouth.  Sent home with Epi Pen.
Information has been received from a 22 year old female patient who in May 2007, was vaccinated with a first 0.5 mL dose of Gardasil. On an unspecified date in 2007, she was vaccinated with a second dose and in November 2007, she was vaccinated with her third dose of Gardasil. There was no concomitant medication. In June 2007, the patient experienced joint pain that first occurred in her upper shoulder then spread to her wrist, hip and knees. She reported that joint pain occurred since a month after the first dose of Gardasil and was still occurring. Additional information is not available.
Rash; This case was reported by a other health professional via interactive digital media and described the occurrence of rash in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was not recovered/not resolved.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication.
Patient received PNEUMOVAX in the right arm. He then developed a fever later that night that continued to the next day and some pain at the injection site. He took ADVIL for the fever which helped and the fever has now resolved as of the morning of August 27th. He developed redness at the site of injection on the 26th which spread slightly further down the arm the morning of the 27th. Patient will continue to monitor for any worsening side effects. He also received a flu shot the same day on the left arm.
injection site had a raised bump the size of a half dollar coin and redness spread out beyond injection site.; injection site had a raised bump the size of a half dollar coin and redness spread out beyond injection site.; injection site had a raised bump the size of a coin and redness spread out beyond injection site.; This is a spontaneous report received from contactable reporter(s) (Nurse) from a sales representative.  A 51-year-old female patient received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), as dose number unknown, single (Lot number: FJ2606, Expiration Date: Jul2023) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE MASS (non-serious), VACCINATION SITE ERYTHEMA (non-serious), ERYTHEMA (non-serious), outcome "unknown" and all described as "injection site had a raised bump the size of a coin and redness spread out beyond injection site.".  Follow-up attempts are completed. No further information is expected.
Information has been received from a physician concerning a 9-year old (previously reported as 8) female with no known allergies who was vaccinated with a dose of varicella virus vaccine live (Oka/Merck) when she was approximately 12 months old. On an unspecified date the patient experienced 250 lesions all over her body that was described as a papular rash with some red, some blistered, some crusted after receiving varicella virus vaccine live (Oka/Merck). It was reported that patient has new lesions daily since last evaluation with an increased itch "most itchy on head" (no relief with oatmeal baths). On 31-JUL-2007, the patient had an oral temperature of 98.5. The patient sought unspecified medical attention. The patient was previously treated with Benadryl at increased doses, calamine, oatmeal baths and ibuprofen which was alternated with Tylenol. On 31-JUL-2007, the patient's physician stopped the Benadryl and prescribed hydroxyzine 12.5-25 mg by mouth six times a day, as well as Tylenol/ibuprofen for "temps". A product quality complaint  was not involved. On 31-JUL-2007, she also experienced a "throat painful". Additional information is not expected.
11 years of age patient received a dose of Twinrix; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 11-year-old female patient who received HAB (Twinrix) (batch number 2KE55, expiry date 22nd September 2023) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 17th August 2022, the patient received Twinrix and Twinrix Pre-Filled Syringe Device. On 17th August 2022, unknown after receiving Twinrix and Twinrix Pre-Filled Syringe Device, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 18-AUG-2022 Reporter's comments: Medical assistant reported that patient 11 years of age received a dose of Twinrix.  The reporter consented to follow up.  The Vaccine Administration Facility was the same as Primary Reporter. Additional supportive information: Medical assistant reported that patient 11 years of age received a dose of Twinrix, which led to inappropriate age at vaccine administration.
Patient + for covid on        10-10-2020 and was vaccinated after had covid on 12-30-2020  He deceased on 11-15-21 .  I have no other information.   This was most likely his first vaccine as it was 12-2020 .
Skin hurt - stomach upset. Mood became awful. Headache, screaming - crying. Muscles achy.  Noise never heard before.
Flu-like symptoms started immediatedly and continued after the expected days (1-2 days). The rest of the week I experienced fever, body aches, shortness of breath and sweats. On Saturday 1/23/21 I took COVID19 test and the results were positive.  I had no symptoms before the vaccine.
One month after vaccine developed rash. Eventual biopsy with eosinophilic vasculitis., later neuropathy
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 28-AUG-2013 the patient was vaccinated with ZOSTAVAX (lot# J001005, expiration date 24-APR-2014) 0.65 ml, subcutaneously. The pharmacist reported that the patient received an improperly stored ZOSTAVAX. The last temperature that was recorded for the ZOSTAVAX was within the recommended storage range (0.1F) was on 21-AUG-2013. The highest temperature recorded since then was 22 F. The patient's outcome was unknown. This is one of two reports from the same source (related to MARRS 1309USA004207). Additional information is not expected.
elevated blood pressure (195/115mmHg); This spontaneous case was reported by a consumer and describes the occurrence of BLOOD PRESSURE INCREASED (elevated blood pressure (195/115mmHg)) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced BLOOD PRESSURE INCREASED (elevated blood pressure (195/115mmHg)). At the time of the report, BLOOD PRESSURE INCREASED (elevated blood pressure (195/115mmHg)) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Blood pressure measurement: 195/115 High.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       There was no treatment information provided. There were no concomitant medication provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-051434, MOD21-075683 (E2B Linked Report). This case was linked to MOD-2021-077046 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of this event, a causal relationship cannot be excluded. US-MODERNATX, INC.-MOD-2021-051434: MOD21-075683:
This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Lightheadedness) and VACCINATION SITE PAIN (Soreness at the site of injection) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029A21A) for COVID-19 vaccination. No Medical History information was reported. On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced VACCINATION SITE PAIN (Soreness at the site of injection). On 11-Mar-2021, the patient experienced DIZZINESS (Lightheadedness). At the time of the report, DIZZINESS (Lightheadedness) and VACCINATION SITE PAIN (Soreness at the site of injection) had not resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. For mRNA-1273 (COVID 19 Vaccine Moderna) (Unknown), the reporter did not provide any causality assessments. No concomitant medications were provided. Treatment medication was not provided by the reporter.
Information has been received from a medical assistant referring to a patient of unknown age and gender. Information about concurrent condition, concomitant medication and medical history was not provided. On 28-JAN-2019, the patient was vaccinated with improperly stored PEDVAXHIB (1 injection, via intramuscular, lot # reported as R0123571 was invalid, expiration date was reported as 19-MAR-2021; strength and anatomical location were not reported) for prophylaxis. No adverse effect was reported. The PEDVAXHIB was exposed to 0 degree Celsius for 45 minutes. There was no previous temperature excursion. The data logger was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1902USA008818: US-009507513-1903USA006922: US-009507513-1903USA006924: US-009507513-1903USA006925: US-009507513-1903USA006926: US-009507513-1903USA006927: US-009507513-1903USA006928: US-009507513-1903USA006929: US-009507513-1903USA006930: US-009507513-1903USA006931: US-009507513-1903USA006932: US-009507513-1903USA006933: US-009507513-1903USA006934: US-009507513-1903USA006935: US-009507513-1903USA006936: US-009507513-1903USA006937: US-009507513-1903USA006938: US-009507513-1903USA006939: US-009507513-1903USA006940: US-009507513-1903USA006941: US-009507513-1903USA006942: US-009507513-1903USA006943: US-009507513-1903USA006944: US-009507513-1903USA006945: US-009507513-1903USA006946: US-009507513-1903USA006947: US-009507513-1903USA006948: US-009507513-1903USA006949: US-009507513-1903USA006950.
Client became light headed and dizzy and had an episode of syncope.  EMS alerted, Client regained consciousness.  client laid down for 30 mins. Client escorted to car with no evidence of shakiness or lightheadedness
Entered observation room at 12:34.  At 12:37 approached the paramedic saying she had leg weakness.  Put on EKG monitor and was in Afib. HR 100-110, usually 60.  No signs and symptoms of an allergic reaction.  IV started by paramedic and transported by ambulance to the ER.  Patient says that in ER her HR came down and rhythm was NSR. Given IV Fluids and discharged to home to follow up with PCP. Spoke at 4:30, home resting.  Sore arm and fatigue only complaints at thi stime.
This case was reported by a healthcare professional and described the occurrence of hives in a 10-year-old female subject who was vaccinated with hepatitis B vaccine (manufacturer unspecified) for prophylaxis.  On an unspecified date the subject received 1st dose of hepatitis B vaccine (unknown).  At an unspecified time after vaccination with hepatitis B vaccine, the subject experienced hives.  The subject was treated (not specified) in the doctor's office and the hives resolved after an unknown period of time.  No additional doses of hepatitis B vaccine were given due to the hives.  The healthcare professional considered the event was possibly related to vaccination with hepatitis B vaccine.
This spontaneous report was received from a neurologist via Pfizer, Inc. and refers to a currently 73 year old patient of unknown gender. No medical history or concurrent conditions were reported. On an unknown date the patient was vaccinated with ZOSTAVAX (dosage, dosage number, route of administration, lot # and expiration date were unknown). On an unknown date, the reporter stated that vaccination with ZOSTAVAX caused the patient to become allergic to neomycin. The outcome of being allergic to neomycin was unknown. The reporter considered the event of being allergic to neomycin to be related to ZOSTAVAX. This is one of the two reports received from the same reporter. Additional information has been requested.
This is a spontaneous report received from a non-contactable consumer or other non-HCP. A 40-year-old male patient received the 2nd dose of BNT162B2 (Comirnaty, batch/lot# unknown), single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. Vaccination history included the 1st dose of BNT162B2 (Comirnaty), for COVID-19 immunisation. The patient experienced a minor hangover, with outcome of unknown. Additional information: Patient was generally in good health and very excited to receive the vaccine. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected.
Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Mild.
Skin reaction began 9 days after first dose. An erythematous, pruritic lesion of 9cm diameter appeared on left arm near injection site. This lesion developed numerous small vesicles within it. The following day painful, pruritic, vesicular lesions appeared on both hands, beginning at DIP and PIP joints dorsally but later including MCP joints, hypothenar eminence, and wrist areas on the palmar side as well. Each hand now has at least 10 lesions. Furthermore, a quarter-sized lesion also appeared on left leg. 15 days after first dose, experienced dizziness and new lesions continue to appear on hands, two additional lesions appeared on right foot.